MétaCan
Menu
Back to cohort
Record W4410354446 · doi:10.1016/j.vaccine.2025.127187

What is the current evidence base for measles vaccination earlier than 9 months of age?: Report from an informal technical consultation of the World Health Organization

2025· article· en· W4410354446 on OpenAlexafffund
Anshu Varma, Shelly Bolotin, Gaston De Serres, Arnaud M. Didierlaurent, Kristen Earle, Kurt Frey, Susan Hahné, Daniel Kapelus, L Kendall Krause, Kevin R. McCarthy, William J. Moss, Walter A. Orenstein, Rob van Binnendijk, Dorthe Maria Vittrup, Merryn Voysey, Tom Woudenberg, Naor Bar‐Zeev, Anindya Sekhar Bose, Joachim Hombach, Mick N. Mulders, Laura Nic Lochlainn, Kezia Suwintono, Daniel R. Feikin, Natasha S. Crowcroft

Bibliographic record

VenueVaccine · 2025
Typearticle
Languageen
FieldMedicine
TopicVirology and Viral Diseases
Canadian institutionsUniversité LavalPublic Health Ontario
FundersUniversity of TorontoWorld Health OrganizationGlaxoSmithKlineMedical Research CouncilBill and Melinda Gates Foundation
KeywordsMeaslesVaccinationMedicineMeasles vaccinePediatricsFamily medicineVirologyEnvironmental health

Abstract

fetched live from OpenAlex

Measles is one of the most contagious vaccine preventable diseases, causing severe complications and deaths globally. While vaccination with a measles-containing vaccine (MCV) has prevented millions of measles deaths, recent trends, especially from low- and middle-income countries, are discouraging. Measles cases have increased since 2021 as MCV coverage has decreased; and an estimated 107,500 measles deaths, mostly in children under-five years, occurred in 2023. Thus, a renewed focus on proven and innovative strategies to control measles is needed. The World Health Organization (WHO) recommends a first MCV dose administered at 9-15 months of age (routine MCV1), however MCV1 below 9 months of age (early MCV1) may increase vaccination coverage because uptake of all vaccines tends to be higher the younger the child, and this might protect vulnerable infants earlier in life. However, due to concerns about possible reduced vaccine performance, early MCV1 is not routinely recommended by WHO. WHO hosted an informal technical consultation on December 6-7, 2023, in Geneva, Switzerland to evaluate recent evidence on early MCV1 and identify evidence gaps for policy making. The recent evidence suggests a robust humoral immune response shortly after early MCV1 at 5-8 months of age. Immune blunting of a routine second MCV dose (e.g., MCV2) after early MCV1 was not demonstrated in the presented data. However, 3-7 years after MCV1, children receiving early MCV1 had lower measles antibodies than children receiving routine MCV1, suggesting faster waning of immunity. The totality of evidence on immune blunting remains inconsistent. Meeting participants thought more data are needed before revisiting WHO's current recommendation for a potential revision. Evidence gaps include: understanding measles disease burden and severity in infants; early MCV1 effectiveness and duration; vaccine-induced cellular immunogenicity; whether measles in infants is acquired from other infants or older children or adults; and blunting of routine MCV2. Addressing evidence gaps through targeted studies and measles outbreak investigations, as well as evaluations of country-level introductions of early MCV1 are warranted. Ensuring high MCV1 and MCV2 coverage remains the priority in measles control.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.051
metaresearch head score (Gemma)0.193
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: none
GenreCandidate signal: Other · Consensus signal: none
Teacher disagreement score0.051
Threshold uncertainty score0.272

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0510.193
Meta-epidemiology (narrow)0.0010.002
Meta-epidemiology (broad)0.0070.008
Bibliometrics0.0100.009
Science and technology studies0.0010.002
Scholarly communication0.0060.005
Open science0.0040.003
Research integrity0.0060.006
Insufficient payload (model declined to judge)0.0100.002

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.026
GPT teacher head0.357
Teacher spread0.331 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreOther

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations7
Published2025
Admission routes2
Has abstractyes

Explore more

Same venueVaccineSame topicVirology and Viral DiseasesFrench-language works237,207